Have your say: EU AI Act consultation on high-risk systems

European Union flag ERDERA

The European Commission has opened a public consultation to gather feedback on the implementation of the AI Act’s rules concerning high-risk AI systems. The aim is to collect practical examples, clarify open questions, and inform upcoming Commission guidelines on the classification of high-risk systems and related obligations.

Under the AI Act, high-risk AI systems fall into two main categories:

  • Important for product safety under the Union’s harmonised legislation on product safety
  • Those that can significantly affect people’s health, safety, or fundamental rights in specific use cases listed in the AI Act.

The consultation also addresses responsibilities across the AI value chain, helping to define roles and accountability for all actors involved.
The Commission invites input from a wide range of stakeholders, including AI developers and providers, businesses and public sector users, academia and research organisations, civil society and citizens, regulatory and supervisory authorities.

The deadline is 18 July 2025. Learn more.

News & Updates

You might also be interested in

On 3–4 June, EURORDIS–Rare Diseases Europe and Orphanet convened the rare disease community at ECRD 2026 in Prague around a shared call for coordinated European action, including the forthcoming European Blueprint for Rare Diseases.
The European Rare Diseases Research Alliance (ERDERA), together with the European Reference Networks (ERNs), provides the missing operational layer required to implement the European Biotech Act across the full innovation pathway —from discovery to patient access.
ERDERA will launch its Clinical Trial Call 2026 (ECTC) on 1 July 2026, supporting multinational, GCP‑compliant early‑phase interventional clinical trials in rare diseases.
Pre-announcement describing scope, eligibility and indicative timeline for the ERDERA Clinical Trial Call 2026, expected to open on 1 July 2026.